131 related articles for article (PubMed ID: 37142051)
21. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
22. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.
Ziv E; Erinjeri JP; Yarmohammadi H; Boas FE; Petre EN; Gao S; Shady W; Sofocleous CT; Jones DR; Rudin CM; Solomon SB
Radiology; 2017 Jan; 282(1):251-258. PubMed ID: 27440441
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
24. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
[TBL] [Abstract][Full Text] [Related]
27. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
28. Comparison of real-life data from patients with NGS panel negative and
Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
[TBL] [Abstract][Full Text] [Related]
29. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
30. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
[TBL] [Abstract][Full Text] [Related]
32. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
33. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ
Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782
[TBL] [Abstract][Full Text] [Related]
34. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
35. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
36. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
[TBL] [Abstract][Full Text] [Related]
37. Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations.
Hu Y; Ren S; Chen C; Liang Q; Yu F; Liu W
Thorac Cancer; 2020 Jul; 11(7):2018-2022. PubMed ID: 32415761
[TBL] [Abstract][Full Text] [Related]
38. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
39. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
